CH678337A5 - - Google Patents
Download PDFInfo
- Publication number
- CH678337A5 CH678337A5 CH1833/89A CH183389A CH678337A5 CH 678337 A5 CH678337 A5 CH 678337A5 CH 1833/89 A CH1833/89 A CH 1833/89A CH 183389 A CH183389 A CH 183389A CH 678337 A5 CH678337 A5 CH 678337A5
- Authority
- CH
- Switzerland
- Prior art keywords
- cells
- immune memory
- suspension
- memory cells
- immune
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 claims description 326
- 230000006054 immunological memory Effects 0.000 claims description 142
- 239000000725 suspension Substances 0.000 claims description 84
- 239000000427 antigen Substances 0.000 claims description 66
- 108091007433 antigens Proteins 0.000 claims description 63
- 102000036639 antigens Human genes 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 28
- 230000001717 pathogenic effect Effects 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 20
- 244000052769 pathogen Species 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 16
- 238000001042 affinity chromatography Methods 0.000 claims description 13
- 239000004677 Nylon Substances 0.000 claims description 12
- 229920001778 nylon Polymers 0.000 claims description 12
- 239000011491 glass wool Substances 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 7
- 239000003463 adsorbent Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 238000002649 immunization Methods 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 230000002085 persistent effect Effects 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 description 55
- 241000700159 Rattus Species 0.000 description 23
- 239000002609 medium Substances 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 210000004698 lymphocyte Anatomy 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000000890 antigenic effect Effects 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000012981 Hank's balanced salt solution Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000001840 diploid cell Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000011278 mitosis Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000607142 Salmonella Species 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 229910000831 Steel Inorganic materials 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- 241000711408 Murine respirovirus Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000606860 Pasteurella Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 101150052863 THY1 gene Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000725630 Ectromelia virus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100438957 Mus musculus Cd8a gene Proteins 0.000 description 2
- 101100438963 Mus musculus Cd8b gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000009485 HLA-D Antigens Human genes 0.000 description 1
- 108010048896 HLA-D Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- -1 Lytt Proteins 0.000 description 1
- 101000934342 Mus musculus T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63300726A JP2639834B2 (ja) | 1988-11-30 | 1988-11-30 | 免疫記憶細胞懸濁液およびその調製方法 |
| CA000596787A CA1333887C (en) | 1988-11-30 | 1989-04-14 | Immunity memory cell suspension and method of preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH678337A5 true CH678337A5 (ja) | 1991-08-30 |
Family
ID=25672621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1833/89A CH678337A5 (ja) | 1988-11-30 | 1989-05-17 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2639834B2 (ja) |
| AU (1) | AU603950B1 (ja) |
| CA (1) | CA1333887C (ja) |
| CH (1) | CH678337A5 (ja) |
| DE (1) | DE3913438A1 (ja) |
| FR (1) | FR2646778B1 (ja) |
| GB (1) | GB2230790B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340565C (en) | 1989-06-29 | 1999-05-25 | Thomas B. Okarma | Device and process for cell capture and recovery |
| US6143508A (en) * | 1989-06-29 | 2000-11-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Device and process for cell capture and recovery |
| SE467498B (sv) * | 1990-11-20 | 1992-07-27 | Vera Stejskal | Foerfarande foer in vitro analys av kvicksilverallergier |
| DE19925405C2 (de) * | 1999-06-02 | 2003-02-13 | Bieger Wilfried W | Verfahren zum Nachweis von spezifisch antigenreaktiven Lymphozyten sowie ein Nachweis-Kit zur Durchführung dieses Verfahrens |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0077571A3 (en) * | 1981-10-19 | 1983-10-12 | Ajinomoto Co., Inc. | Process for producing a lymphokine |
| JPH02502424A (ja) * | 1987-03-11 | 1990-08-09 | ザ・チルドレンズ・ホスピタル，インコーポレイテッド | 抗原特異的ｔセルラインの調製法並びに治療のためのその使用 |
| JPS63300727A (ja) * | 1987-05-29 | 1988-12-07 | 古形 勝 | 健康タワシ |
-
1988
- 1988-11-30 JP JP63300726A patent/JP2639834B2/ja not_active Expired - Lifetime
-
1989
- 1989-04-12 AU AU32747/89A patent/AU603950B1/en not_active Ceased
- 1989-04-12 GB GB8908241A patent/GB2230790B/en not_active Expired - Fee Related
- 1989-04-14 CA CA000596787A patent/CA1333887C/en not_active Expired - Fee Related
- 1989-04-24 DE DE3913438A patent/DE3913438A1/de active Granted
- 1989-05-11 FR FR898906179A patent/FR2646778B1/fr not_active Expired - Fee Related
- 1989-05-17 CH CH1833/89A patent/CH678337A5/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GB2230790A (en) | 1990-10-31 |
| CA1333887C (en) | 1995-01-10 |
| DE3913438A1 (de) | 1990-10-25 |
| JPH02150274A (ja) | 1990-06-08 |
| JP2639834B2 (ja) | 1997-08-13 |
| FR2646778A1 (fr) | 1990-11-16 |
| AU603950B1 (en) | 1990-11-29 |
| GB2230790B (en) | 1993-04-21 |
| GB8908241D0 (en) | 1989-05-24 |
| FR2646778B1 (fr) | 1991-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0806959B1 (fr) | Procede de preparation de macrophages et trousses pour la mise en oeuvre de ce procede | |
| CA1337644C (en) | Device and process for cell capture and recovery | |
| EP1993574B1 (fr) | Cellules t regulatrices cd4+cd25+ specifiques pour la greffe de cellules hematopoïetiques et la tolerance immunitaire | |
| JPH10513054A (ja) | 血液もしくは骨髄からの造血幹細胞の濃縮 | |
| JP2001509778A (ja) | 移植片不全または対宿主性移植片病を伴わない同種異系造血幹細胞移植法 | |
| WO2003070921A1 (fr) | PROCÉDÉS DE PRODUCTION DE LYMPHOCYTES ϜδT | |
| CN109679902A (zh) | 一种基于cik免疫细胞的体外诱导扩增方法 | |
| Kedar et al. | In vitro induction of cell-mediated immunity to murine leukemia cells. I. Optimization of tissue culture conditions for the generation of cytotoxic lymphocytes | |
| CH678337A5 (ja) | ||
| Goodman et al. | An improved primary response from mouse spleen cells cultured in vivo in diffusion chambers | |
| Kedar et al. | Studies on the Induction and Expression of T Cell-Mediated Immunity: IV. Non-Overlapping Populations of Alloimmune Cytotoxic Lymphocytes with Specificity for Tumor-Associated Antigens and Transplantation Antigens | |
| WO2005063969A2 (fr) | Methodes d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations | |
| EP0460065B1 (en) | A process for the generation of proliferating cd4 lymphocytes | |
| TW200800241A (en) | Method of using hepatic progenitors in treating liver dysfunction | |
| Drury et al. | Isolation of Θ-Isoantigen-Negative, Antibody-Inhibiting Cells from Normal Mouse Bone Marrow According to Their Density and Surface-Adherent Properties | |
| JP2639835B2 (ja) | 免疫記憶細胞懸濁液の調製方法 | |
| CN1213143C (zh) | 同源异型的造血系统重构细胞的制药应用 | |
| JP4106488B2 (ja) | 同種移植片に対する免疫寛容の誘導および／または白血病処置のための、幹細胞およびｃｄ６枯渇幹細胞の使用 | |
| WO1995002685A1 (en) | Serum-free culture of progenitor cells | |
| CA2500926A1 (en) | Tumor/b-cell hybrid cells and uses thereof | |
| SHIMA et al. | TOSHIYUKI HAMAOKA, YASUYUKI TAKAI, ATSUSHI KOSUGI | |
| JPH0810321A (ja) | 細胞分取方法および細胞集団 | |
| FR2960882A1 (fr) | Co-culture de cellules mononucleees et de cellules mesenchymateuses pour l'obtention de cellules productrices d'il-17 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |